RIPK1 and myeloid sarcoma: Because the C57BL/6 EAE model has a weaker, monophasic disease course (Berard et al., 2010; Bittner et al., 2014) and we observe RIPK1 upregulation, particularly in progressive MS brain samples (Figures 1A and 1B), we wanted to investigate the role of RIPK1 in a progressive model.